Thursday, August 9, 2012

Pluristem Receives Approval To Commence A Phase I/II Study For Muscle Regeneration In Germany

Pluristem Therapeutics, Inc. (NASDAQCM:PSTI; TASE: PLTR), a leading developer of placenta-based cell therapies, ... http://p.ost.im/p/ddntDc
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)